PMID- 35809114 OWN - NLM STAT- MEDLINE DCOM- 20230414 LR - 20230414 IS - 1432-1335 (Electronic) IS - 0171-5216 (Linking) VI - 149 IP - 5 DP - 2023 May TI - The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. PG - 2017-2027 LID - 10.1007/s00432-022-04147-2 [doi] AB - PURPOSE: Anti-PD-1 antibody (anti-PD-1 mAb) showed favorable outcomes in some patients with relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL). However, the role of anti-PD-1 antibody in NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (NK/T-LAHS) remains unclear. Here, we evaluated the efficacy and toxicity of anti-PD-1 antibody-based treatment in NK/T-LAHS patients. METHODS: The clinical data of 98 patients diagnosed with NK/T-LAHS at Sun Yat-sen University Cancer Center and the First Affiliated Hospital of Guangdong Pharmaceutical University from May 2014 to November 2021 were retrospectively analyzed. All patients received anti-HLH [HLH-2004 (etoposide, dexamethasone, cyclosporine A) or DEP-based (liposomal doxorubicin, etoposide, methylprednisolone)] regimen and sequential anti-ENKTL chemotherapy (ChT) combined with anti-PD-1 antibody or not. RESULTS: The overall response rate (ORR) of the anti-PD-1 mAb plus ChT regimens was higher than that of the ChT regimens (73.3% vs. 45.5%, P = 0.041). The toxicity of the anti-PD-1 mAb plus ChT regimens was tolerable. Except for higher rate of neutropenia, no significant difference in adverse events (AEs) was observed between the two groups. When the optimal response to anti-ENKTL was achieved, the median EBV DNA levels in patients who received anti-PD-1 mAb plus ChT were significantly lower than patients who received ChT only (878 copies/mL vs. 18,600 copies/mL, P = 0.001). With a median follow-up of 26.6 months (range 0-65.9 months), the median overall survival (mOS) was 3.5 months (95% CI：2.3-4.7 months). Patients treated with anti-PD-1 mAb plus ChT experienced a longer mOS than those who received ChT only [5.2 months (95% CI: 2.5-7.8 months) vs. 1.5 months (95% CI: 0.5-2.6 months), P = 0.002]. Cox multivariate analysis found that anti-PD-1 mAb was an independent prognostic factor for all NK/T-LAHS patients. CONCLUSION: In conclusion, anti-PD-1 mAb combined with ChT regimens seemed to be associated with prolonged survival in NK/T-LAHS patients and may represent a potentially promising treatment strategy for this population. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - He, Yanxia AU - He Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Gao, Yan AU - Gao Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Ping, Liqin AU - Ping L AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - He, Haixia AU - He H AD - Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Huang, Cheng AU - Huang C AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Bai, Bing AU - Bai B AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Wang, Xiaoxiao AU - Wang X AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Li, Zhiming AU - Li Z AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Cai, Qingqing AU - Cai Q AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Huang, Yuhua AU - Huang Y AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. AD - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Pan, Xueyi AU - Pan X AD - Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China. FAU - Zeng, Wenbin AU - Zeng W AD - Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China. FAU - Liu, Yanan AU - Liu Y AD - Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China. FAU - Huang, Huiqiang AU - Huang H AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. huanghqsysucc@163.com. AD - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. huanghqsysucc@163.com. LA - eng PT - Journal Article DEP - 20220709 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 6PLQ3CP4P3 (Etoposide) SB - IM MH - Humans MH - *Lymphohistiocytosis, Hemophagocytic/drug therapy/diagnosis MH - Retrospective Studies MH - Etoposide MH - *Lymphoma, Extranodal NK-T-Cell/diagnosis MH - *Lymphoma, T-Cell, Peripheral OTO - NOTNLM OT - Anti-PD-1 antibody OT - Epstein-Barr virus OT - Extranodal NK/T-cell lymphoma OT - Hemophagocytic lymphohistiocytosis EDAT- 2022/07/10 06:00 MHDA- 2023/04/14 06:42 CRDT- 2022/07/09 11:13 PHST- 2022/04/22 00:00 [received] PHST- 2022/06/13 00:00 [accepted] PHST- 2023/04/14 06:42 [medline] PHST- 2022/07/10 06:00 [pubmed] PHST- 2022/07/09 11:13 [entrez] AID - 10.1007/s00432-022-04147-2 [pii] AID - 10.1007/s00432-022-04147-2 [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2023 May;149(5):2017-2027. doi: 10.1007/s00432-022-04147-2. Epub 2022 Jul 9.